PDCD1 and renal cell adenocarcinoma: LAG525 combination with spartalizumab (anti-PD-1) exhibited good safety profiles and antitumor activities in melanoma, renal cell cancer and mesothelioma previously treated with PD-1/PD-L1 blockers, suggesting that LAG-3 blockade counteracts prior resistance to these treatments67 (‘NCT02460224’).